AI-generated from publicly available materials.Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium, aimed at enhancing the predictability of antibody manufacturability and developability risks for the pharmaceutical and biotech sectors.
This new consortium has attracted founding members such as AbbVie, argenx, Lundbeck, and Takeda, with an open invitation for other companies to join. Each member will contribute proprietary antibody sequencing data to build what is anticipated to be the largest standardized dataset in the field, targeting a total of 10,000 antibodies. This initiative is designed to create predictive models for antibody developability, addressing current limitations in available datasets.
Antibody developability refers to the properties that determine whether an antibody can be successfully manufactured and brought to clinical use. Early identification of potential barriers is crucial for more efficient candidate selection, especially in challenging therapeutic areas like the central nervous system. The consortium aims to enhance predictive capabilities by pooling diverse datasets, which could significantly expedite the antibody discovery process and ultimately lead to faster therapeutic advancements.
Ginkgo Datapoints will manage the scientific design of the consortium, including sequence selection and high-throughput characterization, while Apheris will utilize its federated infrastructure to ensure that proprietary data remains confidential. The first dataset is expected to be available by early 2027, with future plans to incorporate more complex antibody formats. This collaborative effort underscores the potential for industry-wide data sharing to develop more robust predictive models, thereby accelerating the journey from discovery to patient treatment.